clinical trial · NCT07456696
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Post Traumatic Stress DisorderTSND-201Placebo
brief summary
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
started
Apr 2, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
May 5, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol